Study guide
3.2 Sedatives, Hypnotics, Anxiolytics, and Cross-Tolerance
IC&RC Alcohol and Drug Counselor CADC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Orientation, IC&RC ADC Exam, and Credential Path
1.1 ADC Credential, IC&RC, and CADC Naming 1.2 Administering Board Application Workflow 1.3 Minimum Standards and Eligibility Boundaries 1.4 ADC Blueprint and Study Priorities 1.5 Exam Format, Items, and Time Management 1.6 Scores, Results, Retakes, and Remediation 1.7 Exam-Day Admission, In-Person Testing, and Remote Testing
2 Chapter 2: Addiction Science, Substance-Use Patterns, and Risk Factors
2.1 Disease Model and Biopsychosocial Frame 2.2 Reward Pathways, Learning, and Reinforcement 2.3 Tolerance, Withdrawal, Craving, and Cross-Tolerance 2.4 Substance-Use Progression and Severity Patterns 2.5 Risk and Protective Factors Across the Lifespan 2.6 Prevention, Case Conceptualization, and Domain Integration
3 Substance Classes, Intoxication, Overdose, and Withdrawal
3.1 Alcohol Intoxication, Overdose, and Withdrawal 3.2 Sedatives, Hypnotics, Anxiolytics, and Cross-Tolerance 3.3 Opioids: Intoxication, Overdose, and Withdrawal 3.4 Stimulants: Intoxication, Crash, and Crisis Risk 3.5 Cannabis, Hallucinogens, and Inhalants 3.6 Polysubstance Use and Overdose Triage
4 Co-Occurring Mental Health, Medical, and Trauma Concerns
4.1 Co-Occurring Symptoms and Integrated Screening 4.2 Suicide, Self-Harm, and Crisis Triage 4.3 Medical Red Flags and Substance-Related Health Concerns 4.4 Trauma-Informed Care and ACEs 4.5 Special Populations, Developmental, and Cultural Factors 4.6 Scope, Referral, Collaboration, and Documentation
5 Screening, Interviewing, and Assessment Instruments
5.1 Motivational Assessment Interview Stance 5.2 Screening Purpose and Instrument Selection 5.3 Substance-Use History and Pattern Exploration 5.4 Collateral Information and Testing Interpretation 5.5 Risk, Withdrawal, and Immediate Needs Screening 5.6 Engagement, Culture, and Documentation
6 Diagnosis, Biopsychosocial Assessment, and Level of Care
6.1 Diagnostic Concepts and Scope 6.2 Biopsychosocial Assessment Framework 6.3 Immediate and Ongoing Needs 6.4 Level-of-Care Placement Reasoning 6.5 Case Formulation and Assessment Summary 6.6 Documentation, Referral, and Reassessment
7 Counseling Relationship, Communication, and Motivational Interviewing
7.1 Rapport and the Working Alliance 7.2 Core Communication Skills 7.3 OARS and Reflective Listening 7.4 Ambivalence, Resistance, and Discord 7.5 Change Talk and Stages of Change 7.6 Feedback and Counselor Style
8 Treatment Planning, Case Management, and Referral
8.1 Treatment Plan Anatomy 8.2 Individualized Goals and Objectives 8.3 Relapse Prevention and Continuing Care 8.4 Case Management and Resource Linkage 8.5 Referral and Multidisciplinary Collaboration 8.6 Discharge, Termination, and Continuity of Care
9 Group Counseling, Family Work, and Recovery Pathways
9.1 Group Purpose, Screening, and Norms 9.2 Group Stages, Cohesion, and Facilitation Skills 9.3 Psychoeducation, Skills Groups, and Process Groups 9.4 Family and Support-System Collaboration 9.5 Mutual Help, Peer Support, and Recovery Pathways 9.6 Medication, Culture, and Continuing Care
10 Professional Ethics, Boundaries, and Scope of Practice
10.1 Ethical Frameworks and Decision Making 10.2 Boundaries, Dual Relationships, and Power 10.3 Self-Disclosure, Conflicts of Interest, and Gifts 10.4 Scope of Practice, Competence, and Referral 10.5 Supervision, Consultation, and Team Accountability 10.6 Self-Awareness, Impairment, and Burnout
11 Confidentiality, Documentation, Informed Consent, and Client Rights
11.1 Confidentiality Foundations for ADC Practice 11.2 Releases and Minimum Necessary Disclosure 11.3 Documentation and Record Quality 11.4 Informed Consent and Client Rights 11.5 Mandated Reporting and Safety Exceptions 11.6 Grievances, Records, Storage, and Professional Communication
12 Integrated CADC Case Scenarios and Final Review
12.1 Reading Integrated Case Vignettes 12.2 Blueprint-Weighted Final Review 12.3 Integrated Scenario: First Contact Through Assessment 12.4 Integrated Scenario: Treatment, Referral, and Discharge 12.5 Weak-Domain Remediation and 8-12 Week Study Plan 12.6 Exam Day, Results, and Retake Workflow
3.2 Sedatives, Hypnotics, Anxiolytics, and Cross-Tolerance
Key Takeaways Explain This Topic AI
Benzodiazepines, barbiturates, and Z-drugs are CNS depressants that share cross-tolerance with alcohol.
Sedative-hypnotic withdrawal, like alcohol withdrawal, can be life-threatening (seizures, delirium) and needs a medically supervised taper.
Short-acting benzodiazepine withdrawal can begin in 24-72 hours; barbiturate withdrawal peaks around days 4-7.
Combining sedatives with alcohol or opioids stacks respiratory depression and sharply raises overdose risk.
Legal prescription status never removes substance-use risk; CADCs assess pattern and refer, they do not advise dose changes.
Last updated: June 2026
The sedative-hypnotic class and cross-tolerance
Sedatives, hypnotics, and anxiolytics depress the CNS, mostly by enhancing GABA activity — the same broad mechanism as alcohol. That shared mechanism is why cross-tolerance is a high-yield exam term: a person tolerant to alcohol is often tolerant to benzodiazepines and barbiturates, and the reverse holds. Cross-tolerance is also why physicians can use long-acting benzodiazepines to treat alcohol withdrawal — the drugs substitute for one another at the receptor.
- Subclass Examples Notes
- Benzodiazepines alprazolam, diazepam, lorazepam, clonazepam Most-prescribed; high misuse potential
- Barbiturates phenobarbital, secobarbital Narrow safety margin; lethal in overdose
- Z-drugs (non-benzo hypnotics) zolpidem, eszopiclone, zaleplon Sleep agents; still cause dependence
- Other anxiolytics meprobamate, some muscle relaxants Variable dependence risk
Intoxication looks like alcohol without the odor: drowsiness, slowed thinking, slurred speech, ataxia, impaired memory, falls, poor driving judgment, and reduced capacity to participate in treatment. Benzodiazepines are also notable for causing anterograde amnesia (the inability to form new memories during intoxication), which is why some are used in drug-facilitated assault. The CADC exam does not expect prescribing-level detail — it expects you to recognize CNS depression, safety risk, withdrawal danger, and the need for referral when symptoms exceed counseling scope.
Because many clients arrive on legitimately prescribed benzodiazepines for anxiety, insomnia, or panic, the exam tests your ability to assess pattern rather than assume a problem from the prescription alone. Escalating doses, early refills, using a partner's pills, combining with alcohol, and morning withdrawal symptoms are the behavioral signals that move a prescribed medication into a possible substance-use concern.
Overdose risk and life-threatening withdrawal
Overdose: benzodiazepines alone rarely kill a healthy adult, but barbiturates have a narrow therapeutic window and can be lethal alone. The real danger the exam emphasizes is combination : sedatives plus alcohol or opioids stack respiratory depression rather than simply adding, producing a multiplicative overdose risk. Benzodiazepines are detected in a large share of opioid-overdose deaths for this reason.
Withdrawal is the other life-threatening point. Like alcohol, sedative-hypnotic withdrawal can produce seizures and delirium and must be tapered under medical supervision — abrupt cessation ("cold turkey") is dangerous.
- Drug Withdrawal onset Peak Notes
- Short-acting benzos (e.g., alprazolam) 24-72 hours ~1-4 days Faster, more intense; higher seizure risk
- Long-acting benzos (e.g., diazepam) 2-7 days ~1-2 weeks Delayed; protracted symptoms possible
- Barbiturates 1-2 days ~4-7 days Seizures, delirium, possible death
Withdrawal features include rebound anxiety, insomnia, tremor, sweating, agitation, perceptual disturbances, and — most dangerously — grand mal seizures and delirium . A subset of clients develop protracted withdrawal (sometimes called benzodiazepine-induced neurological dysfunction), with anxiety, insomnia, and perceptual symptoms lingering for weeks to months, which can be mistaken for relapse or a primary anxiety disorder.
The exam may not name the drug class directly: it may describe someone who stopped nightly pills used for months and now appears shaky and disoriented. Treat that as a probable medical-referral item, not a counseling-only one — a medically supervised taper (gradual dose reduction, often switching to a long-acting agent) is the standard, never abrupt cessation.
Scope, assessment, and exam traps
Scope matters. CADCs can educate at a general level, support motivation, coordinate care, document observations, and encourage communication with qualified prescribers. CADCs do not prescribe, change doses, supervise detox independently, or promise a client can quit at home safely.
Applied scenario: a client says she takes extra anxiety medication with wine because the medication alone no longer works and now feels shaky on mornings she skips it. The strongest CADC response is not to advise a taper or sudden stop. It is to assess amount, frequency, last use, prescriber involvement, current impairment, overdose risk, and withdrawal history, then refer or coordinate within consent and agency policy. The morning shakiness signals physical dependence and possible withdrawal — a medical, not motivational, concern.
A useful counseling frame is that the client may be caught between a real anxiety or sleep problem and a medication that now causes harm. Validating the original distress while naming the current risk reduces defensiveness and keeps the client engaged for the medical referral that the situation actually requires.
Focused assessment questions:
What is prescribed, by whom, and at what dose? Are you taking more than directed?
How often, by what route, and when was your last dose?
Do you combine it with alcohol, opioids, or other substances?
Have you ever had a seizure, blackout, or severe symptoms when stopping?
Are you using it to cope, to sleep, or to manage other substance effects?
Exam traps: (1) choosing the "empowering" answer that advises abrupt discontinuation — stopping sedatives suddenly can trigger seizures; (2) assuming legal prescription status removes risk — misuse, dependence, and unsafe combinations are testable even when the drug was prescribed; (3) labeling a client "drug-seeking" without a specific behavioral fact in the stem. Use neutral language: prescribed medication, taking more than directed, using with alcohol, using to cope .
For one-best-answer items, pick the safest action within role boundaries — observe and document impairment, ask about last use and co-use, consult, and refer for medical evaluation when withdrawal or overdose risk appears.